Table 1.

Summary of main reviewed papers-Prazosin as the treatment of posttraumatic stress disorder (PTSD)

Reference	Study design	Dose	Total patients	Major findings
Raskind et al. [20]	Open-label	2 or 5 mg	4	The 4 patients improved on CAPS and CGI scales
George et al. [19]	Meta-analysis	-	191	Prazosin superior to placebo to treat nightmares and general symptoms of the disorder
Peskind et al. [24]	Open-label	Mean dose 9, 5 mg/day	9	Reduced nightmares and severity of PTSD’s symptoms
Raskind et al. [25]	Crossover trial	Mean dose 13 mg/day	10	Improved sleep quality
				Reduced nightmares and hyperarousal symptoms
Taylor et al. [26]	Crossover trial	1–5 mg	11	Improved Mood States Scores (POMS)
Taylor et al. [27]	Crossover trial	2–6 mg	13	Increased sleep time and reduced nigthmares
Raskind et al. [28]	Randomized	13 mg	34 (17 prazosin; 17 placebo)	Reduced nightmares. Improved sleep quality and global clinical status
	Controlled
	Trial
Germain et al. [29]	Randomized	1–15 mg	50 (18 prazosin, 17 CBT, 15 placebo)	Improved sleep quality
	Controlled
	Trial
Raskind et al. [30]	Randomized	15.6 mg	67	Reduced nightmares. Improved sleep quality and PTSD scores (CAPS)
	Controlled
	Trial
Ahmadpanah et al. [31]	Randomized Controlled	1–15 mg	100 (33: prazosin; 34 hydroxyzine; 33 placebo)	Reduced nightmares; Improved sleep quality
	Trial
Khachatryan et al. [34]	Meta-analysis	-	240	Improved sleep quality and reduced PTSD symptoms
Raskind et al. [35]	Randomized	14.8 mg -	271 (135 prazosin; 136 placebo)	Not effective for sleep symptoms
	Controlled	12 mg (women)
	Trial	20 mg (men)
McCall et al. [37]	Randomized	1–20 mg	20 (10 prazosin; 10 placebo)	Improved sleep quality
	Controlled			Not effective for suicidal ideation
	Trial
Verplaetse et al. [45]	Randomized	0	96 (48 prazosin; 48 placebo)	Not effective for PTSD symptoms (CAPS)
	Controlled
	Trial

CAPS: Clinician Administered PTSD Scale, CGI: Clinical Global Impressions Scale, POMS: Profile of Mood States, CBT: Cognitive Behavioral therapy